1. Anti-infection Cell Cycle/DNA Damage Epigenetics Autophagy Apoptosis
  2. Beta-lactamase HDAC Autophagy Apoptosis
  3. Tubastatin A

Tubastatin A 是一种有效的,选择性的 HDAC6 抑制剂,IC50 值为 15 nM,对其选择性是对 HDAC8 的 57 倍多,是其他同工酶的 1000 多倍。Tubastatin A 还抑制 HDAC10MBLAC2

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Tubastatin A Chemical Structure

Tubastatin A Chemical Structure

CAS No. : 1252003-15-8

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥500
In-stock
5 mg ¥410
In-stock
10 mg ¥650
In-stock
50 mg ¥810
In-stock
100 mg ¥1300
In-stock
200 mg ¥1950
In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Tubastatin A:

    Tubastatin A purchased from MCE. Usage Cited in: Cell Death Dis. 2022 Oct 21;13(10):888.  [Abstract]

    Construction of HCT116 cell line with stable HDAC6 knockdown. Tubastatin A HCl is HDAC6 selective inhibitor.

    Tubastatin A purchased from MCE. Usage Cited in: J Nutr. 2020 Jul 1;150(7):1790-1798.  [Abstract]

    Effects of TBSA (Tubastatin A) pretreatment on glucose-induced changes in mRNA amounts of genes in IECs of yellow catfish.

    Tubastatin A purchased from MCE. Usage Cited in: Front Pharmacol. 2018 Feb 1;9:34.  [Abstract]

    HDAC6 inhibition with Tubastatin A acetylates TFEB, facilitates TFEB nuclear translocation and attenuates programmed cell death in NRK-52E cells. Immunoblotting for acetylated α-tubulin in NRK-52E cells treated with Tubastatin A.

    Tubastatin A purchased from MCE. Usage Cited in: Medical Science, University of Toronto. 2017 Nov.

    Tubastatin A induces a dose-dependent increase in acetylated α-tubulin levels in NRK-52E cells.
    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

    IC50 & Target[1]

    HDAC6

    15 nM (IC50)

    HDAC8

    854 nM (IC50)

    HDAC1

    16400 nM (IC50)

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    697 IC50
    2006 nM
    Compound: Tubastatin A
    Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 31710483]
    A549 GI50
    > 5 μM
    Compound: 3
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 28038324]
    A549 GI50
    > 5 μM
    Compound: Tubastatin A
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay
    [PMID: 31924504]
    B16 GI50
    40.5 μM
    Compound: Tubastatin A
    Growth inhibition of mouse B16 cells incubated for 48 hrs by MTT assay
    Growth inhibition of mouse B16 cells incubated for 48 hrs by MTT assay
    [PMID: 23009203]
    CAL-27 IC50
    4.6 μM
    Compound: Tubastatin A
    Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay
    [PMID: 28581289]
    HCT-116 GI50
    > 5 μM
    Compound: 3
    Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay
    [PMID: 28038324]
    HCT-116 GI50
    > 5 μM
    Compound: Tubastatin A
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay
    [PMID: 31924504]
    HCT-116 IC50
    2 μM
    Compound: Tubastatin A
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 28953386]
    HCT-116 IC50
    2 μM
    Compound: Tubastatin A
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 27541357]
    HEL IC50
    2.54 μM
    Compound: 27
    Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay
    Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay
    [PMID: 29940115]
    HEL IC50
    3.75 μM
    Compound: 27
    Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay
    [PMID: 29940115]
    HEL IC50
    8.09 μM
    Compound: Tubastatin A
    Antiproliferative activity against human HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 33992929]
    HEL 92.1.7 IC50
    > 2 μM
    Compound: Tubastatin A
    Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay
    Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay
    [PMID: 27541357]
    HEL 92.1.7 IC50
    > 4 μM
    Compound: Tubastatin A
    Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay
    Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay
    [PMID: 28953386]
    HeLa IC50
    2.5 μM
    Compound: Tubastatin A
    Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay
    Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay
    [PMID: 25454270]
    HeLa S3 IC50
    0.031 μM
    Compound: Tubastatin
    Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    [PMID: 28337317]
    HeLa S3 IC50
    2.7 μM
    Compound: Tubastatin
    Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    [PMID: 28337317]
    HeLa S3 IC50
    2.9 μM
    Compound: Tubastatin
    Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    [PMID: 28337317]
    HeLa S3 IC50
    3.9 μM
    Compound: Tubastatin
    Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA
    [PMID: 28337317]
    HL-60 IC50
    2.54 μM
    Compound: 27
    Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay
    Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay
    [PMID: 29940115]
    HL-60 IC50
    3.75 μM
    Compound: 27
    Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay
    [PMID: 29940115]
    HL-60 IC50
    4.09 μM
    Compound: Tubastatin A
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 33992929]
    Huh-7 CC50
    11 μM
    Compound: Tubastatin A
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    [PMID: 31201063]
    HUVEC IC50
    29.17 μM
    Compound: TubA
    Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay
    Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay
    [PMID: 36182802]
    HUVEC IC50
    69.23 μM
    Compound: Tubastatin A
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 33992929]
    Jurkat IC50
    14.58 μM
    Compound: Tubastatin A
    Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 33992929]
    Jurkat IC50
    3.38 μM
    Compound: Tubastatin A
    Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 24304348]
    K562 IC50
    2.07 μM
    Compound: Tubastatin A
    Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay
    [PMID: 37146520]
    K562 IC50
    2.54 μM
    Compound: 27
    Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay
    Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay
    [PMID: 29940115]
    K562 IC50
    3.75 μM
    Compound: 27
    Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay
    [PMID: 29940115]
    KB IC50
    14.81 μM
    Compound: Tubastatin A
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    [PMID: 25899338]
    KG-1 IC50
    8.82 μM
    Compound: Tubastatin A
    Antiproliferative activity against human KG-1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human KG-1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 33992929]
    LNCaP IC50
    10.88 μM
    Compound: Tubastatin A
    Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 24304348]
    MCF7 IC50
    3.7 μM
    Compound: Tubastatin A
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 28953386]
    MCF7 IC50
    3.7 μM
    Compound: Tubastatin A
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 27541357]
    MDA-MB-231 IC50
    10.4 μM
    Compound: Tubastatin A
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 28953386]
    MDA-MB-231 IC50
    10.4 μM
    Compound: Tubastatin A
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 27541357]
    NCI-H929 IC50
    15.42 μM
    Compound: Tubastatin A
    Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 33992929]
    PC-3 GI50
    > 5 μM
    Compound: 3
    Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
    Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
    [PMID: 28038324]
    PC-3 IC50
    8.6 μM
    Compound: Tubastatin A
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    [PMID: 28953386]
    PC-3 IC50
    8.6 μM
    Compound: Tubastatin A
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    [PMID: 27541357]
    Sf21 IC50
    > 10000 nM
    Compound: Tubastatin A
    Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay
    Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay
    [PMID: 31924504]
    Sf9 IC50
    > 2000 nM
    Compound: Tubastatin A
    Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis
    Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis
    [PMID: 27650925]
    Sf9 IC50
    > 30000 nM
    Compound: tubustatin A
    Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    [PMID: 23905680]
    Sf9 IC50
    > 30000 nM
    Compound: tubustatin A
    Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    [PMID: 23905680]
    Sf9 IC50
    > 30000 nM
    Compound: tubustatin A
    Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    [PMID: 23905680]
    Sf9 IC50
    0.0035 μM
    Compound: Tubastatin A
    Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay
    Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay
    [PMID: 27541357]
    Sf9 IC50
    11 nM
    Compound: Tubastatin A
    Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate by fluorescence assay
    Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate by fluorescence assay
    [PMID: 27541357]
    Sf9 IC50
    14 nM
    Compound: Tubastatin A
    Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay
    Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay
    [PMID: 31391882]
    Sf9 IC50
    15 nM
    Compound: Tubastatin A
    Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate
    Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate
    [PMID: 23009203]
    Sf9 IC50
    15 nM
    Compound: tubustatin A
    Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    [PMID: 23905680]
    Sf9 IC50
    16400 nM
    Compound: Tubastatin A
    Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate
    Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate
    [PMID: 23009203]
    Sf9 IC50
    16400 nM
    Compound: tubustatin A
    Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate
    [PMID: 23905680]
    Sf9 IC50
    21 nM
    Compound: Tubastatin A
    Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method
    Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method
    [PMID: 31710483]
    Sf9 IC50
    2490 nM
    Compound: Tubastatin A
    Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based a
    Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based a
    [PMID: 31391882]
    Sf9 IC50
    854 nM
    Compound: tubustatin A
    Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate
    Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate
    [PMID: 23905680]
    SH-SY5Y IC50
    1109.7 nM
    Compound: Tubastatin A
    Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis
    Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis
    [PMID: 27650925]
    SH-SY5Y IC50
    122.1 nM
    Compound: Tubastatin A
    Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis
    Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis
    [PMID: 27650925]
    SH-SY5Y IC50
    3.15 μM
    Compound: Tubastatin A
    Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay
    Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay
    [PMID: 36645952]
    SH-SY5Y IC50
    94.3 nM
    Compound: Tubastatin A
    Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis
    Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis
    [PMID: 27650925]
    THP-1 IC50
    > 10 μg/mL
    Compound: Tubastatin A
    Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay
    [PMID: 25240614]
    THP-1 IC50
    1.9 μg/mL
    Compound: Tubastatin A
    Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay
    Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay
    [PMID: 25240614]
    U-937 EC50
    83 μM
    Compound: Tubastatin
    Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay
    Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay
    [PMID: 29150330]
    Vero IC50
    > 20 μM
    Compound: Tubastatin A
    Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 24304348]
    体外研究
    (In Vitro)

    Tubastatin A 对所有 11 种 HDAC 亚型均有显著选择性,对除 HDAC8 以外的所有亚型的选择性均超过 1000 倍,而对 HDAC8 的选择性约为 57 倍。在同型半胱氨酸 (HCA) 诱导的神经变性试验中,Tubastatin A 从 5 μM 开始显示出剂量依赖性保护,可防止 HCA 诱导的细胞死亡,在 10 μM 时几乎完全保护[1]。100 ng/mL 的 Tubastatin A 可增强 Foxp3+ T 调节细胞 (Tregs) 对体外 T 细胞增殖的抑制[2]。当 α-微管蛋白在成肌过程早期过度乙酰化时,Tubastatin A 在 CC12 细胞中的处理会导致肌管形成受损;然而,当肌管中的 α-微管蛋白过度乙酰化时,肌管就会伸长[3]。最近的一项研究表明,Tubastatin A 治疗可增加细胞弹性,原子力显微镜 (AFM) 测试表明,Tubastatin A 治疗不会对小鼠卵巢癌细胞系 MOSE-E 和 MOSE-L 中的肌动蛋白微丝或微管网络产生剧烈变化[4]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    每日 0.5 mg/kg 的 Tubastatin A 治疗可抑制 HDAC6,从而促进炎症和自身免疫小鼠模型中的 Tregs 抑制活性,包括多种形式的实验性结肠炎和完全主要组织相容性复合体 (MHC) 不相容的心脏同种异体移植排斥[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    分子量

    335.40

    Formula

    C20H21N3O2

    CAS 号
    性状

    固体

    颜色

    Off-white to light yellow

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 12.5 mg/mL (37.27 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.9815 mL 14.9076 mL 29.8151 mL
    5 mM 0.5963 mL 2.9815 mL 5.9630 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.25 mg/mL (3.73 mM); 澄清溶液

      此方案可获得 ≥ 1.25 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1.25 mg/mL (3.73 mM); 澄清溶液

      此方案可获得 ≥ 1.25 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

    以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂: 50% PEG300    50% Saline

      Solubility: 25 mg/mL (74.54 mM); 悬浊液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 98.37%

    参考文献
    Cell Assay
    [1]

    Primary cortical neuron cultures are obtained from the cerebral cortex of fetal Sprague-Dawley rats (embryonic day 17) as described previously. All experiments are initiated 24 hours after plating. Under these conditions, the cells are not susceptible to glutamate-mediated excitotoxicity. For cytotoxicity studies, cells are rinsed with warm PBS and then placed in minimum essential medium containing 5.5 g/L glucose, 10% fetal calf serum, 2 mM L-glutamine, and 100 μM cystine. Oxidative stress is induced by the addition of the glutamate analogue homocysteate (HCA; 5 mM) to the media. HCA is diluted from 100-fold concentrated solutions that are adjusted to pH 7.5. In combination with HCA, neurons are treated with Tubastatin A at the indicated concentrations. Viability is assessed after 24 hours by MTT assay.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2]

    The effects of HDAC6 targeting in dextran sodium sulfate (DSS) and adoptive transfer models of colitis are evaluated, using 10 mice per group. Freshly prepared 4% (wt/vol) DSS (MP Biomedicals) is added daily for 5 days to the pH-balanced tap water of WT B6 mice. Mice are treated daily for 7 days with tubacin or niltubacin (0.5 mg/kg of body weight/day, i.p.), and colitis is assessed by daily monitoring of body weight, stool consistency, and fecal blood. Stool consistency is scored as 0 (hard), 2 (soft), or 4 (diarrhea), and fecal blood (Hemoccult) is scored as 0 (absent), 2 (occult), or 4 (gross). To assess prevention of colitis in a T cell-dependent model, CD4+ CD45RBhi T cells (1×106) isolated from WT mice using magnetic beads (>95% cell purity, flow cytometry) are injected i.p. into B6/Rag1−/− mice plus CD4+ CD25+ Tregs (1.25×105) isolated using magnetic beads from HDAC6−/− or WT mice (>90% Treg purity, flow cytometry) and mice are monitored biweekly for clinical evidence of colitis. To assess therapy of established T cell-dependent colitis, B6/Rag1−/− mice are injected i.p. with CD4+ CD45RBhi cells (1×106). Once colitis has developed, mice also receive CD4+ CD25+ Tregs (5×105 cells) isolated as described above from HDAC6−/− or WT mice or treatment with HDAC6i (tubastatin A) or HSP90i (17-AAG). Mice are monitored for continued weight loss and stool consistency. At the cessation of the study, paraffin sections of colons stained with Alcian Blue or hematoxylin and eosin are graded histologically or evaluated by immunoperoxidase staining for Foxp3+ Treg infiltration.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.9815 mL 14.9076 mL 29.8151 mL 74.5379 mL
    5 mM 0.5963 mL 2.9815 mL 5.9630 mL 14.9076 mL
    10 mM 0.2982 mL 1.4908 mL 2.9815 mL 7.4538 mL
    15 mM 0.1988 mL 0.9938 mL 1.9877 mL 4.9692 mL
    20 mM 0.1491 mL 0.7454 mL 1.4908 mL 3.7269 mL
    25 mM 0.1193 mL 0.5963 mL 1.1926 mL 2.9815 mL
    30 mM 0.0994 mL 0.4969 mL 0.9938 mL 2.4846 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Tubastatin A
    目录号:
    HY-13271A
    需求量: